Literature DB >> 852496

Methodology and results of a survey of adverse reactons to a drug in private practice.

A Spriet, C Spriet, C Larousse, D Chigot, M Roux, P Simon.   

Abstract

A survey of tolerance of a drug, determined in private practice under "naturalistic" conditions by 591 physicians, and involving 22277 patients is presented. The procedure used in private practice to gather systematic information about reactions to the drug involved a system of data sheets with detachable cards for optical reading and computer analysis. The survey was conducted under the responsiblity at regional level of a team of scientific coordinators-hospital pharmacologists and poison control centres. Possible side effects were noticed in 13,82% of patients, a figure similar to known nocebo reactions. Tolerance was significantly related to sex, age, weight, geographical area, duration of treatment, association with other durgs and therapeutic result. When related to individual physicians, the overall number of side effects and the frequency of three of them in particular did not follow a binomial distribution; the rate of adverse reactions was significantly related to the number of years of practice of the physicians.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 852496     DOI: 10.1007/BF00606408

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  STUDIES ON THE EPIDEMIOLOGY OF ADVERSE DRUG REACTIONS. I. METHODS OF SURVEILLANCE.

Authors:  L E CLUFF; G F THORNTON; L G SEIDL
Journal:  JAMA       Date:  1964-06-15       Impact factor: 56.272

2.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

3.  Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

4.  The use of computers in international drug monitoring.

Authors: 
Journal:  WHO Chron       Date:  1973-11

5.  Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System.

Authors:  G D Friedman; M F Collen; L E Harris; E E Van Brunt; L S Davis
Journal:  JAMA       Date:  1971-08-02       Impact factor: 56.272

6.  Adverse nondrug reactions.

Authors:  M M Reidenberg; D T Lowenthal
Journal:  N Engl J Med       Date:  1968-09-26       Impact factor: 91.245

7.  Systematic errors in the evaluation of side effects.

Authors:  C W Avery; B P Ibelle; B Allison; N Mandell
Journal:  Am J Psychiatry       Date:  1967-01       Impact factor: 18.112

8.  Adverse drug reactions: a pharmacist-based monitoring system.

Authors:  P Gardner; L J Watson
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

9.  Intensive hospital monitoring of adverse reactions to drugs.

Authors:  N Hurwitz; O L Wade
Journal:  Br Med J       Date:  1969-03-01

10.  Intensive monitoring for adverse drug effects in patients discharged from acute medical wards.

Authors:  G S Kellaway; E McCrae
Journal:  N Z Med J       Date:  1973-12-26
View more
  4 in total

1.  Effect of adverse drug reactions on length of stay in intensive care units.

Authors:  E Vargas; J Simón; J C Martin; M Puerro; M A Gonzalez-Callejo; M Jaime; B Gomez-Mayoral; F Duque; A Gomez-Delgado; A Moreno
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 2.  Detection of drug-induced disease.

Authors:  D H Lawson
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

3.  Difficulties in assessing the adverse effects of drugs.

Authors:  M S Kramer
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

4.  Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents.

Authors:  J E Byfield; J Murnane; J F Ward; P Calabro-Jones; M Lynch; F Kulhanian
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.